# Comparison of Safety, Effectiveness and Quality of Life Outcomes Between Labeled Versus "Treat and Extend" Regimen in Turkish Patients With Choroidal Neovascularisation Due to Age-related Macular Degeneration (AMD)

> **NCT01148511** · PHASE4 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 99 (actual)

## Conditions studied

- Age-related Macular Degeneration

## Interventions

- **DRUG:** Ranibizumab 0.5 mg

## Key facts

- **NCT ID:** NCT01148511
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-02
- **Primary completion:** 2012-04
- **Final completion:** 2012-04
- **Target enrollment:** 99 (ACTUAL)
- **Last updated:** 2013-05-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01148511

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01148511, "Comparison of Safety, Effectiveness and Quality of Life Outcomes Between Labeled Versus "Treat and Extend" Regimen in Turkish Patients With Choroidal Neovascularisation Due to Age-related Macular Degeneration (AMD)". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT01148511. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*